New drug targets tough pancreatic cancer mutation in 60-Patient trial
NCT ID NCT07303465
First seen Jan 05, 2026 · Last updated Apr 25, 2026 · Updated 19 times
Summary
This study tests an experimental drug called RNK08954 in 60 adults with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). The goal is to see if the drug can slow tumor growth and what side effects it may cause. Participants must have measurable tumors and be between 18 and 75 years old.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Tianyinshan Hospital
RECRUITINGNanjing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai GoBroad Cancer Hospital China Pharmaccutical University
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.